Trial · NCT03135548
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 | BI 655130 Low Dose | 31.6 | Percentage of participants (%) | ||
| Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 | BI 655130 High Dose | 31.6 | Percentage of participants (%) | ||
| Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 | Placebo Matching to BI 655130 | 23.8 | Percentage of participants (%) | ||
| Number of Participants With Drug-related Adverse Events (AEs) | BI 655130 Low Dose | 8 | Participants | ||
| Number of Participants With Drug-related Adverse Events (AEs) | BI 655130 High Dose | 8 | Participants | ||
| Number of Participants With Drug-related Adverse Events (AEs) | Placebo Matching to BI 655130 | 9 | Participants | ||
| Percentage of Participants With Palmoplantar Pustular Psoriasis Area and Severity Index 75 (ppPASI75) at Week 16 | BI 655130 Low Dose | 0.0 | Percentage of participnats (%) | ||
| Percentage of Participants With Palmoplantar Pustular Psoriasis Area and Severity Index 75 (ppPASI75) at Week 16 | BI 655130 High Dose | 21.1 | Percentage of participnats (%) | ||
| Percentage of Participants With Palmoplantar Pustular Psoriasis Area and Severity Index 75 (ppPASI75) at Week 16 | Placebo Matching to BI 655130 | 9.5 | Percentage of participnats (%) | ||
| Percent Change From Baseline in the ppPASI at Week 16 | BI 655130 Low Dose | -32.74 | Standard Deviation 38.52 | Unit on scale | |
| Percent Change From Baseline in the ppPASI at Week 16 | BI 655130 High Dose | -45.80 | Standard Deviation 27.00 | Unit on scale | |
| Percent Change From Baseline in the ppPASI at Week 16 | Placebo Matching to BI 655130 | -39.97 | Standard Deviation 32.94 | Unit on scale | |
Percentage of Participants Achieving Treatment Success (Treatment Success Defined as Achieving a Clinical Response of 0 or 1=Clear/Almost Clear) Via Palmoplantar Pustulosis Physicians Global Assessment (pppPGA) at Week 16 | BI 655130 Low Dose | 0.0 | Percentage of participants (%) | ||
Percentage of Participants Achieving Treatment Success (Treatment Success Defined as Achieving a Clinical Response of 0 or 1=Clear/Almost Clear) Via Palmoplantar Pustulosis Physicians Global Assessment (pppPGA) at Week 16 | BI 655130 High Dose | 15.8 | Percentage of participants (%) | ||
Percentage of Participants Achieving Treatment Success (Treatment Success Defined as Achieving a Clinical Response of 0 or 1=Clear/Almost Clear) Via Palmoplantar Pustulosis Physicians Global Assessment (pppPGA) at Week 16 | Placebo Matching to BI 655130 | 14.3 | Percentage of participants (%) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03135548/results